Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you omit radiation in ER/PR negative DCIS patients who are otherwise low risk?
Answer from: Radiation Oncologist at Community Practice
I have usually favored RT in this setting.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
I would favor RT.
Sign in or Register to read more
11649
12759
Related Questions
Would you offer APBI to a patient with very large breast anatomy and a small lumpectomy cavity after an oncoplastic closure?
Would you recommend MRI post surgery and pre-irradiation for patients with extensive DCIS and close margins and how would it impact your management?
Would you consider partial breast irradiation in patients who otherwise meet PBI guidelines who have a pathogenic variant of CHEK2 or other moderate penetrance gene?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
When utilizing hypofractionated radiotherapy in the post mastectomy setting, are the nodal regions dose painted to a different dose or the same dose as the chest wall/reconstructed breast?
What hotspot and heterogeneity metrics do you utilize when delivering PMRT to a patient who has had breast reconstruction?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
Would you recommend PMRT for multifocal IDC with extensive LVI and 1 SLN with ITCs?
In a patient with cardiac comorbidities, who meets ASTRO APBI criteria other than a positive margin, would you offer APBI in an attempt to reduce cardiac dose?
Would you consider once weekly radiation with a simultaneous integrated boost for a patient with node negative breast cancer with a positive margin for whom reexcision is not an option?